After Today’s Significant Increase, Is Global Blood Therapeutics Inc (GBT)’s Near-Term Analysis Positive?

September 17, 2017 - By Kurt Siggers

The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! The stock increased 6.06% or $1.6 on September 15, reaching $28. About 1.68 million shares traded or 137.89% up from the average. Global Blood Therapeutics Inc (NASDAQ:GBT) has risen 43.51% since September 17, 2016 and is uptrending. It has outperformed by 26.81% the S&P500.
The move comes after 5 months positive chart setup for the $1.22B company. It was reported on Sep, 17 by Barchart.com. We have $29.12 PT which if reached, will make NASDAQ:GBT worth $48.80M more.

Investors wait Global Blood Therapeutics Inc (NASDAQ:GBT) to report on November, 8. its quarterly earnings Wall Street analysts expect $-0.61 EPS, down $0.03 or 5.17 % from last year’s $-0.58 same quarter earnings. Global Blood Therapeutics Inc’s Wall Street analysts see 10.91 % negative EPS growth, taking into account the $-0.55 EPS reproted in the previous quarter,

Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage

Among 5 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood Therapeutics had 8 analyst reports since September 8, 2015 according to SRatingsIntel. The firm has “Overweight” rating by JP Morgan given on Wednesday, January 4. The stock has “Buy” rating by Empire on Friday, June 17. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, September 8. Wedbush initiated the shares of GBT in report on Tuesday, September 8 with “Outperform” rating. The firm has “Outperform” rating by Wedbush given on Tuesday, October 25. The rating was initiated by Morgan Stanley with “Overweight” on Tuesday, September 8. The firm has “Outperform” rating given on Tuesday, September 8 by Cowen & Co.

More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: Thestreet.com which released: “Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk” on March 08, 2017, also Globenewswire.com with their article: “Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual …” published on September 06, 2017, Marketwatch.com published: “Global Blood Therapeutics stock surges 5% on eligibility for European priority …” on June 28, 2017. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: Globenewswire.com and their article: “Global Blood Therapeutics Reports Recent Business Progress and Provides Second …” published on August 07, 2017 as well as Seekingalpha.com‘s news article titled: “Global Blood Therapeutics Continues To Be An Attractive Run-Up Play” with publication date: July 06, 2017.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.22 billion. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. It currently has negative earnings. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease .

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.